If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is tirzepatide indicated for patients with type 1 diabetes?
Tirzepatide has not been studied in people with type 1 diabetes.
See important safety information, including boxed warning, in the attached prescribing information.
Use in Patients With Type 1 Diabetes
Type 1 Diabetes
Tirzepatide is not indicated in people with type 1 diabetes (T1D).1
There is no information on the use of tirzepatide in people with T1D because patients with T1D were excluded from tirzepatide clinical trials.
At this time, there are no tirzepatide clinical trials in people with T1D.
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: May 25, 2022